|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,596.00 GBX | +0.61% |
|
-0.72% | +29.88% |
| 03:06pm | Outgoing GSK CEO Emma Walmsley declares US best place to invest | AN |
| 10/12 | Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial | RE |
| Capitalization | 28TCr 24TCr 22TCr 21TCr 38TCr 25,19900Cr 42TCr 2,58500Cr 1,00500Cr 11,90400Cr 1,04800Cr 1,02600Cr 43,37400Cr | P/E ratio 2025 * |
26.6x | P/E ratio 2026 * | 23.4x |
|---|---|---|---|---|---|
| Enterprise value | 30TCr 26TCr 24TCr 22TCr 41TCr 27,12600Cr 45TCr 2,78300Cr 1,08100Cr 12,81400Cr 1,12900Cr 1,10500Cr 46,69200Cr | EV / Sales 2025 * |
5.13x | EV / Sales 2026 * | 4.72x |
| Free-Float |
96.62% | Yield 2025 * |
1.79% | Yield 2026 * | 1.89% |
Last Transcript: AstraZeneca PLC
| 1 day | +0.49% | ||
| 1 week | -0.72% | ||
| Current month | -2.71% | ||
| 1 month | +3.58% | ||
| 3 months | +14.12% | ||
| 6 months | +25.06% | ||
| Current year | +29.88% |
| 1 week | 13,472 |  | 13,848 |
| 1 month | 13,318 | | 14,206 |
| Current year | 9,573.5 | | 14,206 |
| 1 year | 9,573.5 | | 14,206 |
| 3 years | 9,461 | | 14,206 |
| 5 years | 6,736 | | 14,206 |
| 10 years | 3,680 | | 14,206 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 65 | 01/10/2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 51 | 01/08/2021 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 06/04/1999 | |
Pascal Soriot
BRD | Director/Board Member | 65 | 01/10/2012 |
Philip Broadley
BRD | Director/Board Member | 64 | 27/04/2017 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 8.29% | 62 M€ | +15.20% | - |
| 5.39% | 1,412 M€ | +1.24% | - |
| 5.17% | 26 M€ | +11.07% | - |
| 4.89% | 787 M€ | +16.20% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.61% | -0.72% | +29.34% | +19.75% | 28TCr | |
| +1.62% | -0.55% | +26.75% | +174.73% | 89TCr | |
| +1.83% | +3.93% | +43.51% | +18.33% | 50TCr | |
| -0.57% | -2.28% | +28.18% | +35.19% | 40TCr | |
| -1.27% | +1.31% | +25.26% | +4.37% | 34TCr | |
| +0.53% | -1.32% | +19.40% | +23.98% | 25TCr | |
| +2.23% | -1.86% | -0.74% | -9.14% | 24TCr | |
| +3.43% | +5.23% | -59.14% | -30.63% | 21TCr | |
| +0.65% | -6.90% | +15.83% | +14.42% | 17TCr | |
| +1.63% | +0.47% | +33.36% | +39.15% | 15TCr | |
| Average | +1.04% | -2.04% | +16.17% | +29.01% | 34.36TCr | |
| Weighted average by Cap. | +1.05% | -1.92% | +21.32% | +55.64% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 5.86TCr 4.98TCr 4.65TCr 4.37TCr 8.07TCr 5,28400Cr 8.79TCr 54TCr 21TCr 2,49600Cr 22TCr 22TCr 9,09500Cr | 6.23TCr 5.3TCr 4.95TCr 4.64TCr 8.59TCr 5,62000Cr 9.35TCr 58TCr 22TCr 2,65500Cr 23TCr 23TCr 9,67400Cr |
| Net income | 1.05TCr 895.99Cr 836.52Cr 784.82Cr 1.45TCr 95TCr 1.58TCr 9.75TCr 3.79TCr 45TCr 3.95TCr 3.87TCr 1,63500Cr | 1.21TCr 1.03TCr 958.23Cr 899Cr 1.66TCr 1,08800Cr 1.81TCr 11TCr 4.34TCr 51TCr 4.53TCr 4.43TCr 1,87300Cr |
| Net Debt | 2.14TCr 1.82TCr 1.7TCr 1.59TCr 2.94TCr 1,92700Cr 3.21TCr 20TCr 7.68TCr 91TCr 8.02TCr 7.85TCr 3,31800Cr | 1.47TCr 1.25TCr 1.17TCr 1.1TCr 2.03TCr 1,33000Cr 2.21TCr 14TCr 5.3TCr 63TCr 5.53TCr 5.41TCr 2,28900Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/25/11 | 13,596.00 p | +0.61% | 9,45,977 |
| 10/25/10 | 13,514.00 p | -0.57% | 24,85,928 |
| 09/25/09 | 13,592.00 p | +0.10% | 12,32,581 |
| 08/25/08 | 13,578.00 p | -0.10% | 39,39,740 |
| 05/25/05 | 13,592.00 p | +0.58% | 15,01,116 |
Delayed Quote London S.E., December 11, 2025 at 10:05 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition